The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I was looking to do the same, but I have held off thus far.
and before anybody gets upset ...
The Trial is looking at the safety of the combo as well as the efficacy ..
actually the good thing about the new antibody test from Roche .. it should also test for antibodies generated via a vaccine ... if the vaccine mimics the infection ... in with a chance
put it this way if your body has already cleared it, the odds are pretty high that next time the infection will never get started ...pretty safe for a min of 12 months .. however ... not proven !!! and you know what Drs are like they would never agree that Darwin had the edge without a trial or something .....
but that is like the classic argument on here
well how does Keytruda work ........... locks onto T cells ..
well how does Immunobody work ..... Engages Dendritic cells to produce High Avidity T cells
both statements proven .... yes
so they must be synergistic then ?
no mate that is not proven ...
so which one might fail then and do you have any proof ...
No mate they both work ...
Duh !!
Hi LL,
I've tested the whole family (9) in the hope that we may have had exposure without really knowing, but unfortunately (or perhaps fortunately as I am in the moderate risk age group) we have all tested negative, so care and caution is essential for us all., until a decent second generation vaccine becomes available.
Not that i know of .. but i suggest wait 12 months anyway
Thank you for that insight. It is good to hear that at least some have immunity - understanding the longevity will be key. I do hope you daughter stays safe. I'm also concerned about those who work in open plan offices, retail, and eating establishments. . . Contactless payment and "no touch" policies will help, but are not perfect.
I'm was thinking about conditions which may take up to two years to develop.. already the incidence of Kawasaki and others is up as a result of covid19.
Top of the morning Inan,
That would be great if we can obtain a test kit, are there any out there yet?
Bunsie ... its memory B cells that you need to look for, these are the folks that reactivate and flood the infection with secreted antibodies
Hi LL,
My daughter works front line in the Ambulance service and a few of her colleagues have had mild infection to Covid 19 and tested positive (PCR). Out of interest we did a colloidal gold based igm/igg rapid test (10 minutes) from a good supplier, specificity 97.02%, sensitivity 94.03% and conformity 95.96%. The infection date was perhaps 3 to 4 weeks before we tested. The result was positive for igg, negative for igm, which is as to be expected. We may do another test in a further month to check if he still has the antibodies, but in the meantime we assume he has some immunity. He is well with no further complications which is good news.
Genuine question, Given that even a mild case of Covid can raise the likelihood of other (more rare) diseases to rise, how can we deal with that? I think we are just at the beginning of our understanding of secondary effects.
I have been thinking that anyone who deal with lots of strangers / is in places where lots of strangers pass through may need a strong dose (including all those who work in retail, use public transport, etc).
yes which brings me back to the importance of a vaccine that can induce the right parameters in the elderly being far more important than a vaccine that hardly protects the young ... gives them confidence and allows them to spread the virus while getting a mild dose of Covid .
Certainly, T cell depletion is looking like a sure sign of a severe disease outcome...
As well as the track and trace and isolate campaign getting to know just who is most likely to die from this disease as in who's immunity is likely to be compromised by it is going to be very important to getting on top of this pandemic and getting back to any kind of normality.
That's frightening crumbs ... and explains why T cell counts collapse ...
in which case a "potent T cell" that is active against the pathogen could be more important than we suspected ..
Worrying HIV comparisons too:
'Novel coronavirus attacks and destroys T cells, just like HIV'
https://www.news-medical.net/news/20200413/Novel-coronavirus-attacks-and-destroys-T-cells-just-like-HIV.aspx
Interesting Crumbs ....... cancer plays that game to .,.. hence High Avidity may overcome reduced recognition
Tying in with this virus being able to interfere in the immune response a Chinese paper:
The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I
Abstract
SARS-CoV-2 infection have caused global pandemic and claimed over 5,000,000 tolls. Although the genetic sequences of their etiologic viruses are of high homology, the clinical and pathological characteristics of COVID-19 significantly differ from SARS. Especially, it seems that SARS-CoV-2 undergoes vast replication in vivo without being effectively monitored by anti-viral immunity. Here, we show that the viral protein encoded from open reading frame 8 (ORF8) of SARS-CoV-2, which shares the least homology with SARS-CoV among all the viral proteins, can directly interact with MHC-I molecules and significantly down-regulates their surface expression on various cell types. In contrast, ORF8a and ORF8b of SARS-CoV do not exert this function. In the ORF8-expressing cells, MHC-I molecules are selectively target for lysosomal degradation by an autophagy-dependent mechanism. As a result, CTLs inefficiently eliminate the ORF8-expressing cells. Our results demonstrate that ORF8 protein disrupts antigen presentation and reduces the recognition and the elimination of virus-infected cells by CTLs. Therefore, we suggest that the inhibition of ORF8 function could be a strategy to improve the special immune surveillance and accelerate the eradication of SARS-CoV-2 in vivo.
https://www.biorxiv.org/content/10.1101/2020.05.24.111823v1